ProMIS Neurosciences (PMN) News
NASDAQ: PMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.16-0.05 (-1.56%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PMN news summary
We found 9 recent headlines mentioning ProMIS Neurosciences (PMN): 2 in the past week and 7 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, PMN is down 1.56% at $3.16. The most recent story, "ProMIS Licenses TXP1 From Ossianix To Deliver Alzheimer's & Parkinson's Therapies To Brain", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ProMIS Neurosciences headlines
- ProMIS Licenses TXP1 From Ossianix To Deliver Alzheimer's & Parkinson's Therapies To Brain(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, on Tuesday announced signing a license agreement with Ossianix Inc. for TXP1, a brain shuttling technology with…NasdaqPMN, CFR
- ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and PipelineTXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by OssianixGlobeNewswire
- ProMIS (PMN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- ProMIS Neurosciences, Inc. Updates Corporate Presentation, Projects Cash Runway Through 2027ProMIS Neurosciences, Inc. posted an updated corporate presentation on November 11, 2026, highlighting its clinical pipeline and financial outlook. The company reported that its current cash runway…Nasdaq
- ProMIS Neurosciences to Participate in Upcoming Conferences in NovemberCAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic…GlobeNewswire
- 4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesFour biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.NasdaqTGTX, RGNX, IMNM, PMN
- Can Pharmacy Growth Offset Evernorth's Profit Decline in Cigna's Q3?CI's Q3 revenues are poised to rise on pharmacy and premium growth, but declining Evernorth profits and higher medical costs could weigh on earnings.NasdaqCI, HUM, PAHC, PMN
- Will HCA Healthcare's Q3 Earnings Benefit From Higher Admissions?HCA's Q3 results could benefit from higher admissions, occupancy and inpatient revenues, but rising costs and fewer outpatient surgeries cloud the outlook.NasdaqHCA, ILMN, PAHC, PMN
- Can Higher Admissions Offset Rising Costs in UHS' Q3 Earnings?Universal Health Services' Q3 revenues are expected to rise on higher patient admissions, but surging operating costs and wage pressures could weigh on earnings growth.NasdaqUHS, ILMN, PAHC, PMN